IGF-1 analogue
IGF-1 LR3
IGF-1 LR3 is an engineered IGF-1 analogue with much lower affinity for IGF-binding proteins; a 2026 review places it in tier D and lists no peer-reviewed human studies from its literature search.1
IGF-1 LR3 after one dose: 50% at ~20 h, 25% at 40 h, 12.5% at 60 h.
Drawn from the half-life in the app's model, ~20 h. The model's figures
- Compound
- IGF-1 LR3
- Symbol
- LR3
- Family
- Growth hormone peptides
- Parts
- 14
- References
- 18
- Checked
- Last reviewed . Sources are listed below.
Overview
IGF-1 LR3, also written IGF1-LR3, LR3IGF-I and Long R3 IGF-I, is an engineered analogue of insulin-like growth factor 1 (IGF-1).1,2 It differs from native IGF-1 by arginine in place of glutamic acid at position 3 and an additional N-terminal amino acid extension, which together give a markedly reduced affinity for IGF-binding proteins.1
Dominikowski and colleagues, in a 2026 narrative review in Frontiers in Endocrinology, place IGF-1 LR3 in tier D, which they describe as having no peer-reviewed human studies.1 The experiments cited below were done in cell lines, rats, guinea pigs, pigs and sheep.3,4,2,5,6
The 2026 review lists the half-life of IGF-1 LR3 as not documented, against the app's figure of about 20 hours.1 In rats, LR3IGF-I was cleared from plasma more rapidly than IGF-I.7
The WADA 2026 Prohibited List names IGF-1 and its analogues among the growth factors prohibited at all times.8
How it works
Structure and binding
Francis and colleagues, Journal of Molecular Endocrinology, 1992, described Long [Arg3]-IGF-I as an IGF-I sequence carrying an N-terminal extension made from the first 11 amino acids of methionyl porcine growth hormone, with glutamate 3 replaced by arginine.3 Ballard and colleagues, Growth Regulation, 1993, reported that "IGF-I has approximately 1000 fold higher affinity than LR3IGF-I towards IGFBP-3, IGFBP-4, total rat plasma IGFBPs and L6 myoblast BP".4 King and colleagues, Journal of Molecular Endocrinology, 1992, concluded for [Gly3]-IGF-I and [Arg3]-IGF-I, which they made by cleaving the fusion protein and so without the N-terminal extension that LR3IGF-I carries, that "reduced binding to IGF-binding proteins rather than increased receptor binding is the likely explanation for the greater biological potency of the analogues compared with IGF-I".10
Lord and colleagues, Journal of Endocrinology, 1994, compared plasma from the rat, sheep, human, pig and chicken, with des(1-3)IGF-I and LR3IGF-I as the IGF-I variants: the variants bound extremely weakly in rat plasma but bound significantly in plasma from the other species, by size-exclusion chromatography the extent of variant binding "decreased in the order sheep > human > pig = chicken > rat", and in competition for labelled IGF-I binding the order was "pig = chicken > sheep > human > rat".11
The 2026 review states that IGF-1 acts primarily as an agonist at the IGF-1 receptor, activating pathways including PI3K–Akt and MAPK/ERK, and that, as IGF-1 LR3 engages the same receptor, it is "generally presumed to elicit comparable downstream signalling", although "its altered binding characteristics may influence the magnitude or temporal dynamics of pathway activation".1
What the cell and animal experiments measured
In L6 rat myoblasts, Francis and colleagues found that the Long IGF-I analogues were more potent than IGF-I, but in chicken embryo fibroblasts, a cell line that does not secrete detectable IGF-binding proteins into the medium, Long [Arg3]-IGF-I was less potent than IGF-I.3 In normal female rats given the peptides for 14 days, Ballard and colleagues reported that LR3IGF-I was 6 fold more potent than IGF-I in the growth measurements.4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~20 h
- Bioavailability
- 95%
- Typical dose
- 20–60 mcg/day
- Route
- SubQ
- Time to peak
- ~1 h
The 2026 review states that no peer-reviewed clinical studies in humans have reported the route of administration of IGF-1 LR3 and lists its half-life as not documented.1
| Figure | The app's figure | What the sources report |
|---|---|---|
| Half-life | ~20 hours | The 2026 review lists it as not documented.1 In rats, metabolic clearance of LR3IGF-I was 9.84 ± 0.28 ml/min per kg in virgin and 9.19 ± 0.15 in pregnant animals, against 0.90 ± 0.05 and 2.88 ± 0.12 for IGF-I.7 For native IGF-1, the Increlex label gives a mean terminal half-life of 5.8 hours after a single 0.12 mg/kg subcutaneous dose in 3 subjects aged 12 to 22 years with severe primary IGF-1 deficiency.12 |
| Bioavailability | 95% | The 2026 review gives no bioavailability figure for IGF-1 LR3. For native IGF-1, the Increlex label estimates absolute bioavailability after subcutaneous administration in healthy subjects as close to 100%.1,12 |
| Time to peak | ~1 hour | The 2026 review lists no time to peak for IGF-1 LR3.1 |
| Route | Subcutaneous | The 2026 review states that no peer-reviewed clinical studies in humans have reported the route of administration.1 Tomas and colleagues gave IGF-I and LR3IGF-I to rats under the skin, by osmotic pump or by injection, and Bastian and colleagues gave intravenous boluses to rats.13,7 |
| Typical dose | 20–60 mcg/day | The 2026 review's dosing table lists 20-40 µg/day, once daily, from bodybuilding-related forums, and its table note says the regimens mix peer-reviewed and forum-derived sources; the IGF1-LR3 line is cited to forums (a Swolverine blog post), which the review describes as non-peer-reviewed, often internally inconsistent online protocols.1 |
In rats with chronic renal failure, Gillespie and colleagues reported that total clearance of LR3IGF-I was significantly increased, while total clearance of IGF-I was not significantly altered.14
Human studies
Sources in this part
Dominikowski and colleagues, at Poznan University of Medical Sciences, searched PubMed, Google Scholar and the Cochrane Library for English-language publications from January 1989 to January 2026, and placed IGF-1 LR3 in tier D.1 They describe the tier D compounds as having no peer-reviewed human studies and being "supported only by preclinical extrapolation and grey-literature user narratives".1 The authors state that the work is a narrative review that "does not constitute a systematic review". They report no external funding, with the article processing charge partially funded by the Fundacja Rozwoju Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, which they state was not involved in the manuscript, and no commercial or financial relationships that could be construed as a potential conflict of interest.1
The review lists its own limits: no pre-registered protocol, no PRISMA reporting and no formal risk-of-bias appraisal; compounds chosen by how often they are encountered in clinical practice and described on unregulated user platforms; and residual selection bias.1 Its generative AI statement says AI tools assisted with language editing and "initial literature screening", with all citations verified by the authors against primary sources.1
On exogenous IGF-1 in general, not IGF-1 LR3 specifically, the review states that "direct interventional evidence in healthy humans demonstrating consistent improvements in skeletal muscle mass or strength with exogenous IGF-1 is limited".1 In clinical populations, with neuromuscular disorders given as an example, it adds, interventions combining IGF-1 with IGFBP-3 have been associated with increases in lean body mass without clear improvements in functional outcomes.1
Studies in cells and animals
The PubMed records for the 1992 to 1997 papers in the table list affiliations such as the Cooperative Research Centre for Tissue Growth and Repair, CSIRO Division of Human Nutrition and the University of Adelaide, and give no funder or disclosure statement. The 2025 sheep paper states its funding and is analysed below.6
| Study and year | Design | Animals or cells | Dose and length | Main result |
|---|---|---|---|---|
| Francis and colleagues, 19923 | Cell experiments with Long [Arg3]-IGF-I against IGF-I and des(1-3)IGF-I | L6 rat myoblasts, H35 hepatoma cells, chicken embryo fibroblasts | Cell culture | More potent than IGF-I in L6 myoblasts; in chicken embryo fibroblasts, which do not secrete detectable IGFBPs, less potent than IGF-I. |
| Tomas and colleagues, 19929 | Osmotic pumps under the skin, with dexamethasone-induced catabolism | 150 g male rats | IGF-I up to 695 µg/day; dexamethasone 20 µg/day; 7 days; the LR3IGF-I dose is not stated in the PubMed record | LR3IGF-I and des(1-3)IGF-I were approx. 2.5-fold more potent than IGF-I; IGF-I and the analogues increased gut weight by up to 45%, and fractional carcass weights remained low in the IGF-treated groups. |
| Conlon and colleagues, 19952 | Continuous infusion against recombinant guinea pig IGF-I and IGF-II | Female guinea pigs, 350 g | LR3IGF-I 120 µg/day; 7 days | Fractional weights (g/kg body weight) of adrenals, gut, kidneys and spleen rose, but overall growth was not stimulated; plasma IGF-I, IGF-II and IGF-binding proteins fell (per the study title). Weight gain, feed intake and carcass composition were not significantly affected by any treatment. |
| Tomas and colleagues, 199715 | Bolus glucose-lowering comparison with IGF-I and four variants in pigs; IGF-I and des(1-3)IGF-I in marmosets | Pigs and marmosets | Pigs: 20 and 50 µg/kg IGFs; blood sampled to 4 hours | The variants were 2- to 3-fold more potent than IGF-I for lowering glucose to the nadir, with 4- to 8-fold greater cumulative suppression over 4 hours. |
| Dunaiski and colleagues, 19975 | Infusion of LR3IGF-I or IGF-I, alone or with porcine GH | Finisher pigs | LR3IGF-I 180 µg/kg/day; 4 days | LR3IGF-I decreased average daily gain, food intake and plasma IGFBP-3, IGF-I and insulin, and mean GH fell by 23%; plasma glucose was unaffected by any treatment. |
| White and colleagues, 20256 | Randomised twin comparison with vehicle; NIH-funded | Growth-restricted fetal sheep, 7 per group completing | 1.17 ± 0.12 µg/kg/h into the fetal circulation; 7.6 ± 0.3 days | Growth, insulin and glucose-stimulated insulin secretion did not differ from vehicle (fetal weight 14% higher, not significant); adrenal glands were heavier on LR3; amino acids fell; four LR3 fetuses died where the twin survived, and 6 of 13 treated ewes lost at least one fetus after treatment began (2 lost both). |
Deeper analysis: fetal sheep, White and colleagues, 2025
White and colleagues, at the University of Colorado and the University of Arizona, exposed pregnant sheep to elevated ambient temperatures to produce placental insufficiency and fetal growth restriction, and randomly assigned one twin per ewe to IGF-1 LR3 and the other to vehicle.6 The IGF-1 LR3 came from GroPep Bioreagents and was infused into the fetal circulation at 1.17 ± 0.12 µg/kg/h for 7.6 ± 0.3 days.6
Among the 7 LR3 and 7 vehicle fetuses that completed treatment, fetal body weights, insulin, glucose, oxygen and glucose-stimulated insulin secretion did not differ between groups.6 Summed amino acids fell on LR3 (from 3,269 ± 241 to 2,888 ± 301 µmol/L) but not on vehicle (from 3,361 ± 210 to 3,493 ± 202 µmol/L).6 The authors had earlier reported that 6.6 µg/kg/h in normal fetal sheep "increased body weight but lowered insulin concentrations and GSIS".6
The paper reports that "IGF-1 LR3 treatment was associated with fetal demise in four animals".6 Of 18 ewes, 3 had a deceased fetus at surgery and 2 more lost a fetus before treatment; of the remaining 13, 6 lost one (4 ewes) or two (2 ewes) fetuses after treatment began, and the 7 with no demise were analysed.6 In 2 of the 6 ewes both fetuses died, so vehicle-treated twins also died; the paper counts only the four single-twin demises as associated with LR3.6
The four fetuses that died were all male (weight range 0.85 to 3.25 kg) and showed hypoglycaemia and hypoxaemia.6 Glucose decreased by 42% and arterial oxygen pressure by 30% during LR3 treatment (time-by-treatment P = 0.0319 and P = 0.0300).6 Three of the four died in the final 1 to 2 days of treatment at a final dose of 1.12 ± 0.30 µg/kg/h (average final fetal weight 2.21 ± 0.61 kg).6 The fourth, infused at 6.78 µg/kg/h (final fetal weight 0.85 kg), died within 2 days, and the authors note that this was by chance a severely growth-restricted fetus, so it is difficult to compare directly with larger fetuses.6
The authors write that they "may not have delivered a sufficient dose of IGF-1 LR3 to observe improvement in islet function and increased fetal growth", that they were "unable to measure plasma IGF-1 LR3", and that their earlier study used singleton pregnancies whereas this one used twins.6 They add that it is "not possible to conclude whether the lack of statistically significant growth we observed was dose-related or due to nutrient and oxygen supply constraints".6 The work was supported by National Institutes of Health grants, and the authors declare no conflicts of interest.6
Deeper analysis: rat clearance, Bastian and colleagues, 1993
Bastian and colleagues gave intravenous boluses of radiolabelled IGF-I and LR3IGF-I to virgin rats and to rats on day 18 of pregnancy, when plasma IGFBPs, in particular IGFBP-3, are dramatically reduced.7 IGF-I was cleared more rapidly in pregnant than in virgin rats (2.88 ± 0.12 against 0.90 ± 0.05 ml/min per kg), while LR3IGF-I cleared at similar rates in both (9.19 ± 0.15 and 9.84 ± 0.28 ml/min per kg).7 The authors concluded that "the reduction in IGFBP during pregnancy dramatically increased the clearance of IGF-I from the circulation towards that obtained with LR3IGF-I".7
Doses reported in studies
The table below gives the doses reported in the animal experiments and the human-use figure that the 2026 review summarises from online forums.1
| Source | Subjects | Dose and route | Length |
|---|---|---|---|
| Conlon and colleagues, 19952 | Female guinea pigs | LR3IGF-I 120 µg/day by continuous infusion | 7 days |
| Dunaiski and colleagues, 19975 | Finisher pigs | LR3IGF-I 180 µg/kg/day, infusion | 4 days |
| Shoubridge and Read, 200316 | Preweaning and adult rats | 2.6 µg/kg, intravenous bolus | Blood and tissue sampled at 5 and 10 minutes |
| White and colleagues, 20256 | Growth-restricted fetal sheep | 1.17 ± 0.12 µg/kg/h into the fetal circulation | 7.6 ± 0.3 days |
| Dominikowski and colleagues, 20261 | Not a study: fitness- and bodybuilding-related online forums and industry sources, as summarised in the review, with the dose cited to a Swolverine blog post | 20-40 µg/day, once daily, under the skin or into muscle | Not a study length |
The app's typical dose is 20–60 mcg/day; the forum-reported figure in the 2026 review is 20-40 µg/day, a forum-cited line in a table that the review says mixes peer-reviewed and forum-derived regimens, the forum ones being non-peer-reviewed, often internally inconsistent online protocols.1
Side effects reported
In the 2026 review's table, the entries for IGF1-LR3 include "No peer-reviewed human studies" and "Theoretical mitogenic potential based on IGF-1/IGF-1R signalling biology".1 For the whole group of peptides it covers, the review's summary lists reported adverse effects spanning "endocrine and metabolic disturbances", fluid retention syndromes, musculoskeletal symptoms and injection-site reactions, which are not attributed to IGF-1 LR3 alone.1 It writes that reported adverse effects in off-label settings "frequently centre on insulin-mimetic activity", and that "many such reports originate from non-clinical sources".1
In animals, IGF-1 LR3 was associated with fetal demise in four growth-restricted fetal sheep, with hypoglycaemia and hypoxaemia in all four.6 In finisher pigs, a 4-day LR3IGF-I infusion decreased average daily gain, food intake and plasma IGFBP-3, IGF-I and insulin, and plasma glucose was unaffected by any treatment in that study.5
For native IGF-1, not IGF-1 LR3, the Increlex label reports hypoglycemia at least once in 30 of 71 subjects (42%) with primary IGF-1 deficiency, treated for a mean of 3.9 years with subcutaneous doses generally ranging from 0.06 to 0.12 mg/kg twice daily, with 5 subjects having severe hypoglycemia and 4 having hypoglycemic seizures or loss of consciousness.12 The label states that most cases were mild or moderate in severity, and that no subject withdrew from a clinical study because of adverse reactions.12 The label states that "several cases of malignant neoplasia have been observed in pediatric patients treated with INCRELEX".12 The label calls these postmarketing reports, says it is unknown whether there is any relationship with INCRELEX therapy, and says the cases were mostly in patients with rare genetic conditions of short stature associated with an increased risk of cancer or with other cancer predisposing conditions, and were seen more often at higher than recommended doses.12
Bloodwork and markers
The app lists IGF-1, blood glucose and insulin as markers. In the animal experiments, LR3IGF-I infusion in pigs lowered plasma IGF-I, IGFBP-3 and insulin while plasma glucose was unaffected by any treatment, and in guinea pigs the study title reports reduced plasma IGF-I, IGF-II and IGF-binding proteins.5,2 In the 7 LR3 and 7 vehicle growth-restricted fetal sheep that completed treatment, endogenous IGF-1, insulin and glucose concentrations did not differ between groups over the treatment period.6
Gajanandana and colleagues, Journal of Endocrinology, 1998, described an ELISA that "permits discrimination between the exogenous synthetic IGF-I analog and the endogenous native IGFs-I and -II in animals treated with this growth factor".17 The sheep study authors state that they were unable to measure plasma IGF-1 LR3.6
Regulatory and anti-doping status
The WADA 2026 Prohibited List, in section S2.3 on growth factors and growth factor modulators, lists "Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues".8 S2 sits in the part of the list headed substances and methods prohibited at all times, and the S2.3 entry does not name IGF-1 LR3 individually.8
Thomas and colleagues, of the Center for Preventive Doping Research at the German Sport University Cologne, reported in Analyst, 2011, a nano-UPLC mass spectrometry urine method in which the synthetic analogue longR(3)-IGF-1, "assumed to be subject to misuse by cheating athletes", was detected in fortified urine samples.18 They identified an N-terminally truncated degradation product, Des1-10-longR(3)-IGF-1, as the more stable target. The method was validated for qualitative purposes, with a limit of detection of 20-50 pg/mL and recovery of 10-35%, reported for the method as a whole.18
The 2026 review refers to the "absence of regulatory approval for physique- or performance-related indications" for the peptides it covers, which include IGF-1 LR3.1 The IGF-1 product with a US label among the sources is Increlex (mecasermin, recombinant human IGF-1), first approved in 2005 for growth failure in paediatric patients aged 2 years and older with severe primary IGF-1 deficiency or growth hormone gene deletion with neutralising antibodies to growth hormone.12
What is not known
The 2026 review documents no half-life and no route of administration for IGF-1 LR3 from human studies, and lists no peer-reviewed human studies.1 The app's half-life of about 20 hours, bioavailability of 95% and time to peak of about 1 hour are not matched by a figure for IGF-1 LR3 in the 2026 review.1 In rats LR3IGF-I increased growth measures,4 while in finisher pigs it decreased average daily gain;5 Lord and colleagues found that variants of IGF-I bound human plasma proteins more than rat plasma proteins.11 The review adds that "mechanistic plausibility for tier-D compounds does not constitute clinical evidence".1
Frequently asked questions
What is IGF-1 LR3?
What is the half-life of IGF-1 LR3?
Has IGF-1 LR3 been studied in humans?
The 2026 review, which searched PubMed, Google Scholar and the Cochrane Library for English-language publications from January 1989 to January 2026, lists IGF-1 LR3 as having no peer-reviewed human studies.1
Is IGF-1 LR3 banned by WADA?
How potent is IGF-1 LR3 compared with IGF-1?
In animal experiments LR3IGF-I was more potent than IGF-I in several comparisons: 6 fold in the growth measurements in normal female rats, about 2.5-fold in dexamethasone-treated rats, and 2- to 3-fold for glucose lowering in the pig study.4,9,15 It was less potent than IGF-I in chicken embryo fibroblasts, overall growth was not stimulated in guinea pigs, and growth was reduced in pigs.3,2,5
Does IGF-1 LR3 lower blood sugar?
In pigs, IGF-I variants including LR3IGF-I were 2- to 3-fold more potent than IGF-I for lowering plasma glucose and suppressed it over a much longer period.15 In finisher pigs given a 4-day LR3IGF-I infusion, plasma glucose was unaffected by any treatment.5 In the four growth-restricted fetal sheep that died during LR3 treatment, glucose fell by 42%; among the 7 LR3 and 7 vehicle fetuses that completed treatment, glucose did not differ between groups.6 The 2026 review states that reported adverse effects in off-label settings frequently centre on insulin-mimetic activity, with many such reports originating from non-clinical sources.1
What happened in the fetal sheep study of IGF-1 LR3?
In growth-restricted fetal sheep, fetal growth was not improved in the 7 LR3 fetuses that completed about a week of treatment (1.17 ± 0.12 µg/kg/h); four other treated fetuses died (three at about 1.12 µg/kg/h, one at 6.78 µg/kg/h), and the paper reports that treatment "was associated with fetal demise in four animals".6 The four fetuses showed hypoglycaemia and hypoxaemia, and the authors state that their dose may not have been sufficient to improve growth.6
Is IGF-1 LR3 an approved drug?
The 2026 review states that, with the singular exception of tesamorelin within its approved HIV-lipodystrophy indication, none of the compounds it covers, which include IGF-1 LR3, carry regulatory approval for performance- or appearance-related use.1 The IGF-1 product with a US label among the sources is Increlex (mecasermin, recombinant human IGF-1), first approved in 2005 for paediatric patients with severe primary IGF-1 deficiency or growth hormone gene deletion with neutralising antibodies to growth hormone.12
What are the reported side effects of IGF-1 LR3?
Guides, tools and comparisons
- IGF-1 LR3 dosageA guide that answers a question on this compound.
- Calculator for IGF-1 LR3A calculator set up for this compound.
- Previous in Growth hormone peptides: IGF-1 DESThe compound before this one in the class.
- Next in Growth hormone peptides: IpamorelinThe compound after this one in the class.
References
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMC13322892
- Conlon MA, et al. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol 1995. PMID 7561636
- Francis GL, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 1992. PMID 1378742
- Ballard FJ, et al. Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs. Growth Regul 1993. PMID 7683526
- Dunaiski V, et al. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. J Endocrinol 1997. PMID 9488001
- White A, et al. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. Am J Physiol Endocrinol Metab 2025. PMC11901354
- Bastian SE, et al. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. J Endocrinol 1993. PMID 7693845
- World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
- Tomas FM, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J 1992. PMID 1371669
- King R, et al. Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. J Mol Endocrinol 1992. PMID 1311930
- Lord AP, et al. Differences in the association of insulin-like growth factor-I (IGF-I) and IGF-I variants with rat, sheep, pig, human and chicken plasma-binding proteins. J Endocrinol 1994. PMID 7514204
- Eton Pharmaceuticals. INCRELEX (mecasermin) injection, prescribing information. DailyMed, label with revisions to 10/2025. DailyMed label
- Tomas FM, et al. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol 1996. PMID 8708565
- Gillespie CM, et al. Effects of chronic renal failure on plasma clearance of insulin-like growth factor I, des-(1-3)IGF-I, and LR3IGF-I. Am J Physiol 1996. PMID 8897852
- Tomas FM, et al. IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol 1997. PMID 9415072
- Shoubridge CA, Read LC. Preferential intestinal delivery of long[Arg3] insulin-like growth factor (LR3IGF-I) over IGF-I in preweaning and adult rats. Endocrinology 2003. PMID 12697696
- Gajanandana O, et al. Measurement of an analog of insulin-like growth factor-I in blood plasma using a novel enzyme-linked immunosorbent assay. J Endocrinol 1998. PMID 9582496
- Thomas A, et al. Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. Analyst 2011. PMID 21157622